Diacerein + Glucosamine Sulphate + MSMThird Party Manufacturing in India

This fixed-dose combination brings together three complementary mechanisms for comprehensive management of osteoarthritis. Diacerein is a prodrug that is metabolized to rhein, its active form. Rhein inhibits the interleukin-1 beta system, a key driver of cartilage degradation in osteoarthritis. By reducing IL-1 activity, diacerein decreases the expression of matrix metalloproteinases and other catabolic enzymes that break down cartilage extracellular matrix, while simultaneously upregulating tissue inhibitors of metalloproteinases. This anti-catabolic and pro-anabolic effect helps preserve joint structure. Glucosamine sulphate is a naturally occurring aminomonosaccharide and a fundamental building block of glycosaminoglycans, which are essential components of articular cartilage. It provides the substrate for proteoglycan synthesis, stimulates chondrocyte production of collagen and proteoglycans, and exerts mild anti-inflammatory effects by reducing superoxide radical generation. MSM, or methylsulfonylmethane, is an organic sulfur compound that provides bioavailable sulfur for the synthesis of connective tissue components. It acts as a free radical scavenger, reduces inflammatory cytokine production, and inhibits nuclear factor kappa B activation, thereby reducing pain and inflammation at the joint level.

Therapeutic Uses

This combination therapy is indicated for the management of:

• Osteoarthritis of the Knee and Hip: The combination addresses the three major pathological processes of osteoarthritis: cartilage degradation, inflammation, and pain. Diacerein works as a slow-acting symptomatic drug modifying cartilage structure, while glucosamine provides structural support and MSM offers rapid symptomatic pain relief.
• Chronic Joint Pain and Stiffness: Patients with degenerative joint disease benefit from the sustained improvement in joint mobility and reduction in morning stiffness.
• Post-Traumatic Arthritis: The combination is used in rehabilitation protocols following joint injuries to support cartilage repair and manage inflammatory responses.

Why Manufacturers Choose This Combination

The diacerein, glucosamine sulphate, and MSM combination is one of the most prescribed fixed-dose combinations in the Indian osteoarthritis market. India has a large and growing elderly population with high prevalence of knee osteoarthritis, creating enormous demand for cost-effective combination therapies. Indian PCD pharma companies particularly favor this combination because of its high prescription volumes, well-established efficacy profile, and relatively straightforward tablet formulation. The combination is manufactured at scale by third party manufacturers across India, with consistent demand from both domestic franchise networks and export markets in Asia and Africa. For WHO-GMP certified manufacturers, this combination represents a steady-volume product line with established market acceptance and predictable raw material sourcing through Indian API suppliers.